PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777521
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777521
Global Retinal Disorder Treatment Market to Reach US$22.1 Billion by 2030
The global market for Retinal Disorder Treatment estimated at US$14.6 Billion in the year 2024, is expected to reach US$22.1 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Macular Degeneration, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$13.4 Billion by the end of the analysis period. Growth in the Diabetic Retinopathy segment is estimated at 5.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 11.4% CAGR
The Retinal Disorder Treatment market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.
Retinal disorders, including diabetic retinopathy, macular degeneration, and retinal vein occlusion, are among the leading causes of vision loss worldwide. With the growing aging population and increasing prevalence of diabetes and hypertension, the demand for effective retinal treatments has risen significantly. Advances in pharmacotherapy, laser therapy, and surgical interventions have improved the management of retinal diseases, preventing blindness and enhancing patient quality of life. The rise of targeted biologic therapies and gene-based treatments has also transformed the treatment landscape, offering new hope for patients with previously untreatable retinal conditions. As retinal diseases continue to pose significant public health challenges, research and development efforts are accelerating to bring innovative therapies to the market.
Breakthroughs in anti-VEGF (vascular endothelial growth factor) therapy have revolutionized the treatment of retinal diseases by reducing abnormal blood vessel growth and preventing vision loss. The development of long-acting drug delivery systems, including sustained-release implants and biodegradable eye injections, has minimized the need for frequent treatments, improving patient compliance. Additionally, advancements in gene therapy and stem cell-based treatments are offering promising alternatives for retinal degenerative disorders. The use of AI-driven diagnostics in treatment planning is also enhancing personalized care, ensuring that patients receive the most effective therapies for their specific conditions. These innovations are significantly improving visual outcomes and expanding treatment options for retinal disease patients.
The increasing adoption of biologic drugs, gene therapy, and regenerative medicine has transformed the approach to retinal disorder treatment. The expansion of clinical trials and regulatory approvals for novel therapies has further accelerated market growth. Additionally, the rising demand for outpatient and minimally invasive treatment options has led to the development of laser-based and microinvasive surgical techniques. The increasing use of AI and digital health technologies in retinal disease management is also enhancing patient monitoring and treatment personalization.
The growth in the global retinal disorder treatment market is driven by advancements in biologic therapies, expanding clinical research in gene therapy, and increasing access to innovative treatment options. The rising burden of retinal diseases, along with the growing availability of advanced diagnostic and therapeutic solutions, is fueling market demand. The integration of telemedicine and digital health platforms is further improving patient engagement and treatment adherence. As new treatments continue to emerge, the retinal disorder treatment market is expected to experience sustained growth, offering transformative solutions for vision care worldwide.
SCOPE OF STUDY:
The report analyzes the Retinal Disorder Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Macular Degeneration, Diabetic Retinopathy, Others); Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 36 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.